Skip to content

Study · Observational study · n = 73,702 · 2026

9 results

Comparative Effectiveness of Liraglutide versus Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Multicenter Propensity Score-Matched Real-World Study.

Khalil I, Hossain MI, Sarker P, Nur N, Al-Badri SG, Akter MM, Halder L, Rahman MT, Kamrul-Hasan ABM

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists25 Mar 2026

PMID41895690 (opens in a new tab)DOI10.1016/j.eprac.2026.03.009 (opens in a new tab)PepBankPUB-41895690
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with HFpEF, liraglutide was associated with lower all-cause mortality risk than dulaglutide at 1 year (HR 0.738, 95% CI 0.675-0.806).

    In plain wordsIn adults with HFpEF, liraglutide was linked to lower 1-year mortality versus dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseAll-cause mortality at 1 year
    Study

    n = 73,702

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.738
    versus dulaglutide at 1 year; 95% CI 0.675-0.806

    Source sentences

    Summary
    At 1 year, liraglutide was associated with lower all-cause mortality (hazard ratio [HR] 0.738, 95% CI 0.675-0.806, P < .0001), acute heart failure events (HR 0.862, 0.830-0.894, P < .0001), hospitalization (HR 0.927, 0.901-0.954, P < .0001), stroke (HR 0.900, 0.863-0.939, P < .0001), and hypoglycemi…
    3 context sentences
    Summary · context
    Using the TriNetX US Collaborative Network (November 2025), we identified 99 683 adults with HFpEF who newly initiated liraglutide (n = 37 386) or dulaglutide (n = 62 297).
    Summary · context
    One-to-one propensity-score matching on >50 baseline covariates yielded 36 851 matched pairs for 1-year analysis and 33 686 pairs with 5-years follow-up.
    Summary · context
    Primary outcome was all-cause mortality; secondary outcomes included acute heart failure events, all-cause hospitalization, myocardial infarction, stroke, and hypoglycemia at 1 and 5-years assessed by Kaplan-Meier survival analysis and Cox-proportional hazards models.
  2. 02HumanObservational studyEfficacy outcome

    In adults with HFpEF, liraglutide was associated with lower all-cause mortality risk than dulaglutide at 5 years (HR 0.775).

    In plain wordsIn adults with HFpEF, liraglutide was linked to lower 5-year mortality versus dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseAll-cause mortality at 5 years
    Study

    n = 67,372

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.775
    versus dulaglutide at 5 years

    Source sentences

    Summary
    Benefits persisted and amplified at 5 years: all-cause mortality HR 0.775, acute heart failure HR 0.820, and stroke HR 0.848.
    3 context sentences
    Summary · context
    Using the TriNetX US Collaborative Network (November 2025), we identified 99 683 adults with HFpEF who newly initiated liraglutide (n = 37 386) or dulaglutide (n = 62 297).
    Summary · context
    One-to-one propensity-score matching on >50 baseline covariates yielded 36 851 matched pairs for 1-year analysis and 33 686 pairs with 5-years follow-up.
    Summary · context
    Primary outcome was all-cause mortality; secondary outcomes included acute heart failure events, all-cause hospitalization, myocardial infarction, stroke, and hypoglycemia at 1 and 5-years assessed by Kaplan-Meier survival analysis and Cox-proportional hazards models.
  3. 03HumanObservational studyEfficacy outcome

    In adults with HFpEF, liraglutide was associated with lower risk of acute heart failure events than dulaglutide at 1 year (HR 0.862, reported interval 0.830-0.894).

    In plain wordsIn adults with HFpEF, liraglutide was linked to fewer 1-year heart failure events versus dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseAcute heart failure events at 1 year
    Study

    n = 73,702

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.862
    versus dulaglutide at 1 year; reported interval 0.830-0.894

    Source sentences

    Summary
    At 1 year, liraglutide was associated with lower all-cause mortality (hazard ratio [HR] 0.738, 95% CI 0.675-0.806, P < .0001), acute heart failure events (HR 0.862, 0.830-0.894, P < .0001), hospitalization (HR 0.927, 0.901-0.954, P < .0001), stroke (HR 0.900, 0.863-0.939, P < .0001), and hypoglycemi…
    3 context sentences
    Summary · context
    Using the TriNetX US Collaborative Network (November 2025), we identified 99 683 adults with HFpEF who newly initiated liraglutide (n = 37 386) or dulaglutide (n = 62 297).
    Summary · context
    One-to-one propensity-score matching on >50 baseline covariates yielded 36 851 matched pairs for 1-year analysis and 33 686 pairs with 5-years follow-up.
    Summary · context
    Primary outcome was all-cause mortality; secondary outcomes included acute heart failure events, all-cause hospitalization, myocardial infarction, stroke, and hypoglycemia at 1 and 5-years assessed by Kaplan-Meier survival analysis and Cox-proportional hazards models.
  4. 04HumanObservational studyEfficacy outcome

    In adults with HFpEF, liraglutide was associated with lower all-cause hospitalization risk than dulaglutide at 1 year (HR 0.927, reported interval 0.901-0.954).

    In plain wordsIn adults with HFpEF, liraglutide was linked to lower 1-year hospitalization versus dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseAll-cause hospitalization at 1 year
    Study

    n = 73,702

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.927
    versus dulaglutide at 1 year; reported interval 0.901-0.954

    Source sentences

    Summary
    At 1 year, liraglutide was associated with lower all-cause mortality (hazard ratio [HR] 0.738, 95% CI 0.675-0.806, P < .0001), acute heart failure events (HR 0.862, 0.830-0.894, P < .0001), hospitalization (HR 0.927, 0.901-0.954, P < .0001), stroke (HR 0.900, 0.863-0.939, P < .0001), and hypoglycemi…
    3 context sentences
    Summary · context
    Using the TriNetX US Collaborative Network (November 2025), we identified 99 683 adults with HFpEF who newly initiated liraglutide (n = 37 386) or dulaglutide (n = 62 297).
    Summary · context
    One-to-one propensity-score matching on >50 baseline covariates yielded 36 851 matched pairs for 1-year analysis and 33 686 pairs with 5-years follow-up.
    Summary · context
    Primary outcome was all-cause mortality; secondary outcomes included acute heart failure events, all-cause hospitalization, myocardial infarction, stroke, and hypoglycemia at 1 and 5-years assessed by Kaplan-Meier survival analysis and Cox-proportional hazards models.
  5. 05HumanObservational studyEfficacy outcome

    In adults with HFpEF, liraglutide was associated with lower stroke risk than dulaglutide at 1 year (HR 0.9, reported interval 0.863-0.939).

    In plain wordsIn adults with HFpEF, liraglutide was linked to lower 1-year stroke risk versus dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseStroke at 1 year
    Study

    n = 73,702

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.9
    versus dulaglutide at 1 year; reported interval 0.863-0.939

    Source sentences

    Summary
    At 1 year, liraglutide was associated with lower all-cause mortality (hazard ratio [HR] 0.738, 95% CI 0.675-0.806, P < .0001), acute heart failure events (HR 0.862, 0.830-0.894, P < .0001), hospitalization (HR 0.927, 0.901-0.954, P < .0001), stroke (HR 0.900, 0.863-0.939, P < .0001), and hypoglycemi…
    3 context sentences
    Summary · context
    Using the TriNetX US Collaborative Network (November 2025), we identified 99 683 adults with HFpEF who newly initiated liraglutide (n = 37 386) or dulaglutide (n = 62 297).
    Summary · context
    One-to-one propensity-score matching on >50 baseline covariates yielded 36 851 matched pairs for 1-year analysis and 33 686 pairs with 5-years follow-up.
    Summary · context
    Primary outcome was all-cause mortality; secondary outcomes included acute heart failure events, all-cause hospitalization, myocardial infarction, stroke, and hypoglycemia at 1 and 5-years assessed by Kaplan-Meier survival analysis and Cox-proportional hazards models.
  6. 06HumanObservational studySafety outcome

    In adults with HFpEF, liraglutide was associated with lower hypoglycemia risk than dulaglutide at 1 year (HR 0.891, reported interval 0.808-0.983).

    In plain wordsIn adults with HFpEF, liraglutide was linked to lower 1-year hypoglycemia risk versus dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycemia at 1 year
    Study

    n = 73,702

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.891
    versus dulaglutide at 1 year; reported interval 0.808-0.983

    Source sentences

    Summary
    At 1 year, liraglutide was associated with lower all-cause mortality (hazard ratio [HR] 0.738, 95% CI 0.675-0.806, P < .0001), acute heart failure events (HR 0.862, 0.830-0.894, P < .0001), hospitalization (HR 0.927, 0.901-0.954, P < .0001), stroke (HR 0.900, 0.863-0.939, P < .0001), and hypoglycemi…
    3 context sentences
    Summary · context
    Using the TriNetX US Collaborative Network (November 2025), we identified 99 683 adults with HFpEF who newly initiated liraglutide (n = 37 386) or dulaglutide (n = 62 297).
    Summary · context
    One-to-one propensity-score matching on >50 baseline covariates yielded 36 851 matched pairs for 1-year analysis and 33 686 pairs with 5-years follow-up.
    Summary · context
    Primary outcome was all-cause mortality; secondary outcomes included acute heart failure events, all-cause hospitalization, myocardial infarction, stroke, and hypoglycemia at 1 and 5-years assessed by Kaplan-Meier survival analysis and Cox-proportional hazards models.
  7. 07HumanObservational studyEfficacy outcome

    In adults with HFpEF, liraglutide was associated with lower risk of acute heart failure events than dulaglutide at 5 years (HR 0.820).

    In plain wordsIn adults with HFpEF, liraglutide was linked to fewer 5-year heart failure events versus dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseAcute heart failure events at 5 years
    Study

    n = 67,372

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.82
    versus dulaglutide at 5 years

    Source sentences

    Summary
    Benefits persisted and amplified at 5 years: all-cause mortality HR 0.775, acute heart failure HR 0.820, and stroke HR 0.848.
    3 context sentences
    Summary · context
    Using the TriNetX US Collaborative Network (November 2025), we identified 99 683 adults with HFpEF who newly initiated liraglutide (n = 37 386) or dulaglutide (n = 62 297).
    Summary · context
    One-to-one propensity-score matching on >50 baseline covariates yielded 36 851 matched pairs for 1-year analysis and 33 686 pairs with 5-years follow-up.
    Summary · context
    Primary outcome was all-cause mortality; secondary outcomes included acute heart failure events, all-cause hospitalization, myocardial infarction, stroke, and hypoglycemia at 1 and 5-years assessed by Kaplan-Meier survival analysis and Cox-proportional hazards models.
  8. 08HumanObservational studyEfficacy outcome

    In adults with HFpEF, liraglutide was associated with lower stroke risk than dulaglutide at 5 years (HR 0.848).

    In plain wordsIn adults with HFpEF, liraglutide was linked to lower 5-year stroke risk versus dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseStroke at 5 years
    Study

    n = 67,372

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.848
    versus dulaglutide at 5 years

    Source sentences

    Summary
    Benefits persisted and amplified at 5 years: all-cause mortality HR 0.775, acute heart failure HR 0.820, and stroke HR 0.848.
    3 context sentences
    Summary · context
    Using the TriNetX US Collaborative Network (November 2025), we identified 99 683 adults with HFpEF who newly initiated liraglutide (n = 37 386) or dulaglutide (n = 62 297).
    Summary · context
    One-to-one propensity-score matching on >50 baseline covariates yielded 36 851 matched pairs for 1-year analysis and 33 686 pairs with 5-years follow-up.
    Summary · context
    Primary outcome was all-cause mortality; secondary outcomes included acute heart failure events, all-cause hospitalization, myocardial infarction, stroke, and hypoglycemia at 1 and 5-years assessed by Kaplan-Meier survival analysis and Cox-proportional hazards models.
  9. 09HumanObservational studyEfficacy outcome

    In adults with HFpEF, liraglutide was associated with lower myocardial infarction risk than dulaglutide at 5 years (HR 0.907, reported interval 0.880-0.935).

    In plain wordsIn adults with HFpEF, liraglutide was linked to lower 5-year myocardial infarction risk versus dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseMyocardial infarction at 5 years
    Study

    n = 67,372

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.907
    versus dulaglutide at 5 years; reported interval 0.880-0.935

    Source sentences

    Summary
    Myocardial infarction reduction emerged only at 5 years (HR 0.907, 0.880-0.935, P < .0001).
    3 context sentences
    Summary · context
    Using the TriNetX US Collaborative Network (November 2025), we identified 99 683 adults with HFpEF who newly initiated liraglutide (n = 37 386) or dulaglutide (n = 62 297).
    Summary · context
    One-to-one propensity-score matching on >50 baseline covariates yielded 36 851 matched pairs for 1-year analysis and 33 686 pairs with 5-years follow-up.
    Summary · context
    Primary outcome was all-cause mortality; secondary outcomes included acute heart failure events, all-cause hospitalization, myocardial infarction, stroke, and hypoglycemia at 1 and 5-years assessed by Kaplan-Meier survival analysis and Cox-proportional hazards models.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.